dc.contributor.author | García Sanz, Ramón | |
dc.contributor.author | Sureda, Anna | |
dc.contributor.author | de la Cruz, F | |
dc.contributor.author | Canales, M | |
dc.contributor.author | Gonzalez, A P | |
dc.contributor.author | Pinana, J L | |
dc.contributor.author | Rodriguez, A | |
dc.contributor.author | Gutierrez, A | |
dc.contributor.author | Domingo-Domenech, E | |
dc.contributor.author | Sanchez-Gonzalez, B | |
dc.contributor.author | Rodriguez, G | |
dc.contributor.author | Lopez, J | |
dc.contributor.author | Moreno, M | |
dc.contributor.author | Rodriguez-Salazar, M J | |
dc.contributor.author | Jiménez Cabrera, Silvia | |
dc.contributor.author | Caballero, M D | |
dc.contributor.author | Martinez, C | |
dc.date.accessioned | 2024-02-06T16:52:35Z | |
dc.date.available | 2024-02-06T16:52:35Z | |
dc.date.issued | 2019-04-01 | |
dc.identifier.citation | Garcia-Sanz, R., Sureda, A., De La Cruz, F., Canales, M., Gonzalez, A. P., Pinana, J. L., ... & Martinez, C. (2019). Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Annals of Oncology, 30(4), 612-620. doi:10.1093/annonc/mdz009 | es_ES |
dc.identifier.issn | 0923-7534 | |
dc.identifier.uri | http://hdl.handle.net/10366/155434 | |
dc.description.abstract | [EN]In this work, we assessed the efficacy and safety of brentuximab vedotin (BV) plus ESHAP (BRESHAP) as second-line therapy for Relapsed/Refractory Hodgkin lymphoma (RRHL) to improve the results before autologous stem-cell transplantation (ASCT). This was a multicenter, open-label, phase I-II trial of patients with RRHL after first-line chemotherapy. Treatment had three 21-day cycles of etoposide, solumedrol, high-dose AraC, and cisplatin. BV was administered at three dose levels (0.9, 1.2, and 1.8 mg/kg) intravenous on day ‒1 to 3 + 3 cohorts of patients. Final BV dose was 1.8 mg/kg. Responding patients proceeded to ASCT, followed by three BV courses (1.8 mg/kg, every 21 days). Main end points for evaluation were maximum tolerable dose and overall and complete response (CR) before ASCT. A total of 66 patients were recruited (median age 36 years; range 18-66): 40 were primary refractory, 16 early relapse and 10 late relapse. There were 39 severe adverse events were reported in 22 patients, most frequently fever (n = 25, 35% neutropenic), including 3 deaths. Grade 3-4 hematological toxicity presented in 28 cases: neutropenia (n = 21), thrombocytopenia (n = 14), and anemia (n = 7). Grade ≥3-4 extrahematological adverse events (≥5%) were non-neutropenic fever (n = 13) and hypomagnesaemia (n = 3). Sixty-four patients underwent stem-cell mobilization; all collected >2×10e6/kg CD34+ cells (median 5.75; range 2.12-33.4). Overall response before transplant was 91% (CI 84% to 98%), including 70% (CRs 95% CI 59% to 81%). 60 patients were transplanted with no failure engraftments. Post-transplant response was CR in 49 patients (82% CI 73% to 91%) and partial responses in six (10% CI 5% to 15%). After a mean follow-up of 27 months, the 30-month time to treatment to failure was 74% (95% CI 68% to 80%), progression-free survival 71% (95% CI 65% to 77%), and overall survival 91% (CI 84% to 98%). BRESHAP looks a safe and effective pre-transplant induction regimen, does not jeopardize transplant and allows long-term remissions and survival. | es_ES |
dc.description.sponsorship | Takeda Phamaceuticals Grupo Español de linfoma y traspalnte de médula ósea (GELTAMO) | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/publicdomain/zero/1.0/ | * |
dc.subject | Hodgkin Llymphoma | es_ES |
dc.subject | Relapsed | es_ES |
dc.subject | Refractory | es_ES |
dc.subject | Brentuximab Vedotin | es_ES |
dc.subject | Transplant | es_ES |
dc.subject.mesh | Cisplatin | * |
dc.subject.mesh | Transplantation | * |
dc.subject.mesh | Aged | * |
dc.subject.mesh | Kaplan-Meier Estimate | * |
dc.subject.mesh | Neoadjuvant Therapy | * |
dc.subject.mesh | Young Adult | * |
dc.subject.mesh | Hematopoietic Stem Cell Transplantation | * |
dc.subject.mesh | Adult | * |
dc.subject.mesh | Chemotherapy-Induced Febrile Neutropenia | * |
dc.subject.mesh | Drug Administration Schedule | * |
dc.subject.mesh | Follow-Up Studies | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Adolescent | * |
dc.subject.mesh | Hodgkin Disease | * |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | * |
dc.subject.mesh | Cytarabine | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Etoposide | * |
dc.subject.mesh | Salvage Therapy | * |
dc.subject.mesh | Prednisone | * |
dc.title | Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group) | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publishversion | https://doi.org/10.1093/annonc/mdz009 | es_ES |
dc.subject.unesco | 3207.08 Hematología | es_ES |
dc.identifier.doi | 10.1093/annonc/mdz009 | |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |
dc.identifier.pmid | 30657848 | |
dc.identifier.essn | 1569-8041 | |
dc.journal.title | Annals of Oncology | es_ES |
dc.volume.number | 30 | es_ES |
dc.issue.number | 4 | es_ES |
dc.page.initial | 612 | es_ES |
dc.page.final | 620 | es_ES |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es_ES |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada | * |
dc.subject.decs | etopósido | * |
dc.subject.decs | humanos | * |
dc.subject.decs | anciano | * |
dc.subject.decs | trasplante | * |
dc.subject.decs | estudios de seguimiento | * |
dc.subject.decs | mediana edad | * |
dc.subject.decs | pauta de administración medicamentosa | * |
dc.subject.decs | enfermedad de Hodgkin | * |
dc.subject.decs | adolescente | * |
dc.subject.decs | prednisona | * |
dc.subject.decs | trasplante de células madre hematopoyéticas | * |
dc.subject.decs | adulto | * |
dc.subject.decs | adulto joven | * |
dc.subject.decs | neutropenia febril inducida por quimioterapia | * |
dc.subject.decs | citarabina | * |
dc.subject.decs | tratamiento neoadyuvante | * |
dc.subject.decs | tratamiento de última línea | * |
dc.subject.decs | cisplatino | * |
dc.subject.decs | estimación de Kaplan-Meier | * |
dc.description.project | Grupo Español de linfoma y traspalnte de médula ósea (GELTAMO) | es_ES |
dc.description.project | Spanish GELTAMO Foundation | es_ES |
dc.description.project | Takeda | es_ES |
Parcourir
Tout DSpaceCommunautés & CollectionsPar date de publicationAuteursSujetsTitresCette collectionPar date de publicationAuteursSujetsTitres